$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

$rmtg Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022048156 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$374.4K	$304.5K	$310.1K
YoY Change	126.83%	1831.14%	6883.78%
Cost Of Revenue	$109.4K	$155.9K	$203.6K
YoY Change	23.55%	1214.34%	1276.54%
Gross Profit	$265.0K	$148.6K	$106.5K
YoY Change	246.31%	3702.51%	-1128.89%
Gross Profit Margin	70.79%	48.81%	34.34%
Selling, General & Admin	$387.2K	$478.7K	$622.0K
YoY Change	-95.74%	85.4%	336.41%
% of Gross Profit	146.12%	322.07%	584.11%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$39.88K	$35.33K	$26.98K
YoY Change	207.97%	17562.5%	13390.0%
% of Gross Profit	15.05%	23.77%	25.34%
Operating Expenses	$427.1K	$514.1K	$649.0K
YoY Change	-95.3%	98.92%	354.7%
Operating Profit	-$162.1K	-$365.4K	-$542.5K
YoY Change	-98.2%	43.57%	254.4%
Interest Expense	$1.183M	$1.131M	-$1.134M
YoY Change	-231.46%	156.82%	255.37%
% of Operating Profit
Other Income/Expense, Net		-$1.131M	-$1.141M
YoY Change		389.46%
Pretax Income	-$1.344M	-$1.493M	-$1.677M
YoY Change	-86.44%	61.22%	255.05%
Income Tax
% Of Pretax Income
Net Earnings	-$1.344M	-$1.493M	-$1.677M
YoY Change	-86.44%	61.22%	255.05%
Net Earnings / Revenue	-359.12%	-490.3%	-540.82%
Basic Earnings Per Share	-$0.11	-$0.12	-$0.14
Diluted Earnings Per Share	-$0.11	-$0.12	-$138.7K
COMMON SHARES
Basic Shares Outstanding	12.25M shares	12.22M shares	12.09M shares
Diluted Shares Outstanding	12.25M shares	12.22M shares	12.09M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.770M	$1.925M	$2.461M
YoY Change	-30.02%	-81.66%	212.44%
Cash & Equivalents	$1.770M	$1.925M	$2.461M
Short-Term Investments
Other Short-Term Assets	$0.00	$0.00	$121.3K
YoY Change	-100.0%
Inventory
Prepaid Expenses
Receivables	$86.26K	$23.03K	$60.18K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.856M	$1.948M	$2.643M
YoY Change	-82.78%	-81.87%	235.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$145.1K	$159.1K	$75.86K
YoY Change	461.58%	8741.5%	3693.0%
Goodwill	$5.805M	$5.805M
YoY Change
Intangibles	$378.7K	$403.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.570K	$5.570K	$5.570K
YoY Change		-96.82%	-96.82%
Total Long-Term Assets	$6.376M	$6.422M	$6.314M
YoY Change	1.36%	3532.42%	3467.48%
TOTAL ASSETS
Total Short-Term Assets	$1.856M	$1.948M	$2.643M
Total Long-Term Assets	$6.376M	$6.422M	$6.314M
Total Assets	$8.232M	$8.370M	$8.957M
YoY Change	-51.76%	-23.36%	828.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$279.4K	$230.0K	$378.3K
YoY Change	23.9%	181.18%	3.99%
Accrued Expenses	$4.190M	$3.470M	$2.833M
YoY Change	176.78%	279.58%	345.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$10.00K
YoY Change	-100.0%	-100.0%	-93.25%
Long-Term Debt Due	$1.532M	$1.533M	$1.534M
YoY Change
Total Short-Term Liabilities	$6.077M	$5.298M	$4.824M
YoY Change	-41.26%	363.0%	320.35%
LONG-TERM LIABILITIES
Long-Term Debt	$13.15M	$12.71M	$12.28M
YoY Change	7.51%	98.86%	96.89%
Other Long-Term Liabilities	$8.840K	$16.14K	$23.31K
YoY Change
Total Long-Term Liabilities	$13.16M	$12.73M	$12.31M
YoY Change	7.58%	99.11%	97.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.077M	$5.298M	$4.824M
Total Long-Term Liabilities	$13.16M	$12.73M	$12.31M
Total Liabilities	$19.23M	$18.03M	$17.13M
YoY Change	-14.8%	139.18%	131.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$51.18M	-$49.84M
YoY Change
Common Stock	$12.25K	$12.25K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.00M	-$9.656M	-$8.172M
YoY Change
Total Liabilities & Shareholders Equity	$8.232M	$8.370M	$8.957M
YoY Change	-51.76%	-23.36%	828.5%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.344M	-$1.493M	-$1.677M
YoY Change	-86.44%	61.22%	255.05%
Depreciation, Depletion And Amortization	$39.88K	$35.33K	$26.98K
YoY Change	207.97%	17562.5%	13390.0%
Cash From Operating Activities	-$152.2K	-$396.4K	-$516.1K
YoY Change	-64.66%	-27.17%	233.28%
INVESTING ACTIVITIES
Capital Expenditures	-$1.260K	-$128.6K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$1.260K	-$128.6K
YoY Change	-100.14%	-48.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.460K	-11.42K	-1.400K
YoY Change	-99.42%	-100.11%	-100.16%
NET CHANGE
Cash From Operating Activities	-152.2K	-396.4K	-516.1K
Cash From Investing Activities	-1.260K	-128.6K
Cash From Financing Activities	-1.460K	-11.42K	-1.400K
Net Change In Cash	-154.9K	-536.5K	-517.5K
YoY Change	-165.77%	-105.53%	-169.45%
FREE CASH FLOW
Cash From Operating Activities	-$152.2K	-$396.4K	-$516.1K
Capital Expenditures	-$1.260K	-$128.6K
Free Cash Flow	-$150.9K	-$267.8K	-$516.1K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56010
	dei	Entity Registrant Name EntityRegistrantName	MESO NUMISMATICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0492191
	dei	Entity Address Address Line1 EntityAddressAddressLine1	433 Plaza Real Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	889-9509
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12250888	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1924532	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2978525	usd
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	23027	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1947558	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159147	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	5568	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	403255	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48712	usd
CY2022Q2	us-gaap	Goodwill Goodwill	5805438	usd
CY2022Q2	us-gaap	Assets Assets	8369678	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	230031	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3470334	usd
CY2022Q2	mssv	Customer Advances CustomerAdvances	21430	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	10836	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32568	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1532978	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5298177	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16144	usd
CY2022Q2	mssv	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	35402	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	7800	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	12667655	usd
CY2022Q2	us-gaap	Liabilities Liabilities	18025177	usd
CY2022Q2	mssv	Preferred Stock Value1 PreferredStockValue1	1050	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	10	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13853202	shares
CY2022Q2	mssv	Common Stock Shares Issuable CommonStockSharesIssuable	13853202	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13687439	shares
CY2021Q4	mssv	Common Stock Shares Issuable CommonStockSharesIssuable	13687439	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12250888	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12085125	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	12251	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40170862	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-49839672	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655500	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8369678	usd
CY2022Q2	us-gaap	Revenues Revenues	304521	usd
CY2021Q2	us-gaap	Revenues Revenues	15769	usd
	us-gaap	Revenues Revenues	614599	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	135575	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	381	usd
CY2022Q2	us-gaap	Professional Fees ProfessionalFees	196330	usd
	us-gaap	Revenues Revenues	20212	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	155881	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	11860	usd
	us-gaap	Cost Of Revenue CostOfRevenue	359474	usd
	us-gaap	Cost Of Revenue CostOfRevenue	26650	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	148640	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	3909	usd
	us-gaap	Gross Profit GrossProfit	255125	usd
	us-gaap	Gross Profit GrossProfit	-6438	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	80961	usd
CY2021Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	144	usd
CY2021Q2	us-gaap	Professional Fees ProfessionalFees	215458	usd
	us-gaap	Professional Fees ProfessionalFees	592069	usd
	us-gaap	Professional Fees ProfessionalFees	329245	usd
CY2022Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	22500	usd
CY2021Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	19099	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	45000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	34099	usd
CY2022Q2	us-gaap	Depreciation Depreciation	35325	usd
CY2021Q2	us-gaap	Depreciation Depreciation	200	usd
	us-gaap	Depreciation Depreciation	62302	usd
	us-gaap	Depreciation Depreciation	400	usd
CY2022Q2	mssv	Investor Relations InvestorRelations	47634	usd
CY2021Q2	mssv	Investor Relations InvestorRelations	17574	usd
	mssv	Investor Relations InvestorRelations	94884	usd
	mssv	Investor Relations InvestorRelations	20472	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	131304	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5945	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	233222	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16555	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	514054	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	258420	usd
	us-gaap	Operating Expenses OperatingExpenses	1163052	usd
	us-gaap	Operating Expenses OperatingExpenses	401152	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1131178	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	440457	usd
	us-gaap	Interest Expense InterestExpense	2271708	usd
	us-gaap	Interest Expense InterestExpense	759685	usd
CY2022Q2	mssv	Settlement Of Lawsuit SettlementOfLawsuit	3527	usd
	mssv	Settlement Of Lawsuit SettlementOfLawsuit	9606	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-231109	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-231109	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1493065	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-926077	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3170029	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1398384	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12216471	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10931898	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12154532	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10920888	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6757007	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	251536	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3170029	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655500	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8172434	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1493065	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655500	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-6409571	usd
	mssv	Debt Settlement DebtSettlement	213109	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16040	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10859130	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1398384	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	3300324	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-6504773	usd
CY2021Q2	mssv	Debt Settlement DebtSettlement	213109	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8065	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10500000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-926077	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	3300324	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3170029	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1398384	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	884430	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	219829	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62302	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	9606	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-231109	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20000	usd
	mssv	Imputed Interest On Debt ImputedInterestOnDebt	16040	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5771	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2714	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1323430	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	211835	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-912531	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-699171	usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	128639	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128639	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-250000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11400000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	12823	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12823	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11400000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1053993	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10450829	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2978525	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42534	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1924532	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10493363	usd
	us-gaap	Interest Paid Net InterestPaidNet	207	usd
	mssv	Debt Restructure DebtRestructure	10859130	usd
	mssv	Cancellations Of Preferred Series Bb CancellationsOfPreferredSeriesBB	279	usd
	mssv	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement	213109	usd
	mssv	Issuance Of Preferred Series Dd IssuanceOfPreferredSeriesDD	251536	usd
	mssv	Issuance Of Common Shares For Services IssuanceOfCommonSharesForServices	20000	usd
CY2017Q3	mssv	Share Issuance Of Series Bb Preferred ShareIssuanceOfSeriesBBPreferred	25000	shares
CY2018Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split.
	mssv	Bear Interest Rate Description BearInterestRateDescription	●Assumed certain Convertible Redeemable Notes issued by Lans Holdings Inc. to a lender, pursuant to the Assignment and Assumption Agreement and subject to any pre-existing defaults under the Notes, Meso Numismatics, Inc. reissued an aggregate of $1,079,626 of Convertible Redeemable Notes to the lender which bear interest at a rate varying from ten (10%) to fifteen (15%) percent, and have a one (1) year maturity date.
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	1163357	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	1079626	usd
CY2021Q3	mssv	Purchase Agreement Acquiring Description PurchaseAgreementAcquiringDescription	On August 18, 2021, the Company completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021).
	mssv	Issuance Shares IssuanceShares	1000	usd
	mssv	Cash Payments CashPayments	8200000	usd
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	8200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates in Financial Statement Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the derivative liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q2	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	216716	shares
CY2021Q4	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	75710	shares
CY2022Q2	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	37647060	shares
CY2021Q4	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	37647060	shares
CY2022Q2	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2021Q4	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2022Q2	mssv	Total Outstanding TotalOutstanding	141363776	shares
CY2021Q4	mssv	Total Outstanding TotalOutstanding	141222770	shares
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	10836	usd
CY2022Q2	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	10836	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	20442	usd
CY2021Q4	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	20442	usd
	mssv	Going Concern GoingConcern	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $50 million and a working capital deficit of $3,350,619 as of June 30, 2022 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2022Q2	mssv	Accumulated Deficit AccumulatedDeficit	50000000	usd
CY2022Q2	mssv	Working Capital Deficit WorkingCapitalDeficit	3350619	usd
	us-gaap	Revenues Revenues	614599	usd
CY2021	us-gaap	Revenues Revenues	20212	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	614599	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	359474	usd
	mssv	Revenue Gross Profits RevenueGrossProfits	255125	usd
	mssv	Gross Profits GrossProfits	0.4151	pure
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	8369678	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3170029	usd
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.2
CY2021	mssv	Description Of Convertible Debentures DescriptionOfConvertibleDebentures	The notes are convertible, at the investors’ sole discretion, into shares of common stock at conversion price equal to the lowest bid price of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the three prior trading days including the day upon which a Notice of Conversion is received by the Company.
CY2019Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	81043	shares
CY2019Q4	mssv	Aggregate Exchange Amount AggregateExchangeAmount	97252	usd
	mssv	Payments On The Outstanding Convertible Notes PaymentsOnTheOutstandingConvertibleNotes	10000	usd
CY2021	mssv	Payments On The Outstanding Convertible Notes PaymentsOnTheOutstandingConvertibleNotes	25000	usd
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	251144	usd
CY2022Q2	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	251144	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	62252	usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	72252	usd
CY2015	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.10	pure
CY2022Q2	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	130025	usd
	us-gaap	Long Term Debt Contingent Payment Of Principal Or Interest LongTermDebtContingentPaymentOfPrincipalOrInterest	$86,046
CY2019Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.2
CY2019Q4	mssv	Premium Paid PremiumPaid	0.20	pure
CY2020Q3	mssv	Promissory Debentures Lender Amount PromissoryDebenturesLenderAmount	6000	usd
CY2020Q3	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.18	pure
CY2020Q3	us-gaap	Convertible Debt ConvertibleDebt	5000	usd
CY2020Q3	mssv	Net Of Discount NetOfDiscount	1000	usd
CY2020Q3	mssv	Promissory Debentures Lender Amount PromissoryDebenturesLenderAmount	84000	usd
CY2020Q3	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.18	pure
CY2020Q3	us-gaap	Convertible Debt ConvertibleDebt	70000	usd
CY2020Q3	mssv	Net Of Discount NetOfDiscount	14000	usd
CY2020Q4	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock with three separate lenders. The new notes have a maturity date of November 23, 2023 and an aggregate principal amount of $5,379,624 shall bear interest at a fifteen (15%) percentage compounded annual interest rate and, as an incentive; we have issued cashless warrants to purchase 15,000,000 shares of our common stock at an exercise price of $0.03 per share in connection with the restructuring. The Company recorded the fair value of the 15,000,000 warrants issued with debt at approximately $262,376 at December 31, 2020 as a discount. Lender is granted security interest and lien in all rights, title and interest in the assets and property of the as collateral.
CY2020Q4	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $110,000 which bear compounded annual interest at eighteen (18%) percent and have a two (2) year maturity date and cashless warrants to purchase 1,000,000 shares of our common stock. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $100,000, net of discount in the amount of $10,000 to the Company. The Company recorded the fair value of the 1,000,000 warrants issued with debt at approximately $17,491 at December 31, 2020 as a discount. On January 6, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,000,000 which bear interest at eighteen (15%) percent and have a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. This debt instrument is currently in default as of January 6, 2022. On June 22, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of June 30, 202, the principal balance of the outstanding auto loan was $2,953. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of June 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $133,318. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
CY2021Q1	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $1,000,000 which bear interest at eighteen (15%) percent and have a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. This debt instrument is currently in default as of January 6, 2022.On June 22, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of June 30, 202, the principal balance of the outstanding auto loan was $2,953. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of June 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $133,318. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
CY2021Q2	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral.On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of June 30, 202, the principal balance of the outstanding auto loan was $2,953. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of June 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $133,318. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
CY2021Q3	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount.On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
	mssv	Promissory Notes Payable PromissoryNotesPayable	20240512	usd
CY2021	mssv	Promissory Notes Payable PromissoryNotesPayable	20243335	usd
	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	-5966143	usd
CY2021	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	-6822622	usd
CY2022Q2	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	65936	usd
CY2021Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	82466	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	14208433	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	13338247	usd
	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	2823	usd
CY2021	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	1812	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1387278	usd
CY2021	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1781394	usd
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	856480	usd
CY2021	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	874476	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	3219190	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1878251	usd
CY2022Q2	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20240512	usd
CY2021Q4	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20243335	usd
	mssv	Common Stock Issuablein Shares CommonStockIssuableinShares	216716	shares
	mssv	Market Value Of Common Stock On Measurement Datein Dollars MarketValueOfCommonStockOnMeasurementDateinDollars	0.05
	mssv	Adjusted Exercise Pricein Dollars Per Share AdjustedExercisePriceinDollarsPerShare	0.06
	mssv	Fair Value Assumption Risk Free Interest Rates FairValueAssumptionRiskFreeInterestRates	0.0251	pure
	mssv	Instrument Lives In Years InstrumentLivesInYears	P2Y6M
	mssv	Expected Volatilies ExpectedVolatilies	1.11	pure
CY2021	mssv	Derivative Instruments Additions DerivativeInstrumentsAdditions	24186	usd
CY2021Q4	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	-3744	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	20442	usd
CY2022Q2	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	-7751	usd
	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions	-1855	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	10836	usd
	us-gaap	Debt Conversion Description DebtConversionDescription	the Company may redeem for cash out of funds legally available therefor, any or all of the outstanding Series CC Convertible Preferred Stock at a price equal to $1,000 per share. If not converted prior, on the Automatic Conversion Date, any and all remaining issued and outstanding shares of Series CC Convertible Preferred Stock shall automatically convert at the Conversion Price, which is a price per share determined by dividing the number of issued and outstanding shares of (common?) stock of the Company on the date of conversion by 1,000 and multiply the results by 0.8.
CY2020	mssv	Preferred Stock Price Per Share PreferredStockPricePerShare	83.73
CY2021	mssv	Preferred Stock Price Per Share PreferredStockPricePerShare	83.73
CY2022Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	89485	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2021Q1	mssv	Issuance Of Warrants IssuanceOfWarrants	10000000	shares
CY2021Q1	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	237811	usd
CY2021Q2	mssv	Issuance Of Warrants IssuanceOfWarrants	70000000	shares
CY2021Q2	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	5465726	usd
CY2021Q3	mssv	Issuance Of Warrants IssuanceOfWarrants	7500000	shares
CY2021Q3	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	360607	usd
CY2020	mssv	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P3Y
CY2014Q2	mssv	Aggregate Vote AggregateVote	0.67	pure
CY2021Q3	mssv	Final Payment FinalPayment	225000	usd
CY2021Q3	mssv	Final Payment FinalPayment	50000	usd
	mssv	Convertible Common Stock Description ConvertibleCommonStockDescription	The Series AA Preferred shares issued on August 18, 2021, were valued based upon industry specific control premiums and the Company’s market cap at the time of the transaction. The $963,866 value of the 1,000,000 shares of Series AA Super Voting Preferred Stock issued to Benito Novas were valued based on a calculation by a third party independent valuation specialist.
	mssv	Professional Service Consulting Description ProfessionalServiceConsultingDescription	In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90,000, starting January 1, 2022. Additionally, the agreement included an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022.
	us-gaap	Other Expenses OtherExpenses	503552	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	251776	usd
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	448	shares
CY2021	mssv	Recorded As Stock Payable RecordedAsStockPayable	251536	usd
	mssv	Professional Service Consulting Agreement Description ProfessionalServiceConsultingAgreementDescription	In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90k starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022.
	us-gaap	Payments For Fees PaymentsForFees	15000	usd
CY2021Q4	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	8200000	usd
CY2021Q3	mssv	Stock Purchase Agreement Percentage StockPurchaseAgreementPercentage	1	pure
CY2019Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	20991	usd
CY2021Q1	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	504.94	usd
	mssv	Outstanding Auto Loan OutstandingAutoLoan	2953	usd
CY2021Q3	mssv	Outstanding Share Percentage OutstandingSharePercentage	1	pure
	mssv	Aggregate Amount AggregateAmount	90461	usd
CY2017	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	282500	usd
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	300000	usd
CY2021Q2	mssv	Issued Shares Of Common Stock IssuedSharesOfCommonStock	1092866	shares
CY2021Q2	mssv	Common Stock Settlement Amount CommonStockSettlementAmount	213109	usd
CY2021Q2	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Outstanding Balance CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOutstandingBalance	0	usd
	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	0.275	pure
CY2021Q4	us-gaap	Area Of Land AreaOfLand	1647	sqm
CY2021	us-gaap	Payments For Rent PaymentsForRent	2714	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	5568	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	57469	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43536	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159147	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22909	usd
	mssv	Equipment And Leaseholds Purchased EquipmentAndLeaseholdsPurchased	121332	usd
CY2022Q2	mssv	Equipment And Leaseholds Purchased EquipmentAndLeaseholdsPurchased	28838	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	13933	usd
CY2021Q1	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	400	usd
CY2021Q3	mssv	Outstanding Shares Percentage OutstandingSharesPercentage	1	pure
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	225000	usd
	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The preliminary purchase price for the merger was determined to be $6.229 million, which consists of (i) 1 million shares of Series AA preferred stock valued at approximately $964,000, (ii) 8,974 shares of Series DD preferred stock valued at approximately $5.04 million and (iii) $225,000 in cash of which $175,000 was advanced in prior to closing of the transaction.
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1089976	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12999298	usd
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.13
CY2022Q2	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
CY2021Q4	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
CY2021	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
	mssv	Customer Base CustomerBase	37000	usd
CY2021	mssv	Customer Base CustomerBase	37000	usd
CY2022Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2022Q2	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	84445	usd
CY2021Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	36076	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	403255	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	451624	usd
	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	48369	usd
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	0	usd
	mssv	Monthly Rent MonthlyRent	2714	usd
CY2022Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	5588	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	24427	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	27140	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	51567	usd
CY2022Q2	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	2855	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	48712	usd
CY2022Q2	us-gaap	Advance Rent AdvanceRent	2714	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	5568	usd
CY2022Q1	us-gaap	Payments To Acquire Water Systems PaymentsToAcquireWaterSystems	121332	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q2	mssv	Settlement Of Lawsuit SettlementOfLawsuit		usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue		usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	mssv	Imputed Interest On Debt ImputedInterestOnDebt		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	mssv	Debt Restructure DebtRestructure		usd
	mssv	Cancellations Of Preferred Series Bb CancellationsOfPreferredSeriesBB		usd
	mssv	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement		usd
	mssv	Issuance Of Preferred Series Dd IssuanceOfPreferredSeriesDD		usd
	mssv	Issuance Of Common Shares For Services IssuanceOfCommonSharesForServices		usd
	mssv	Expected Dividend Yields ExpectedDividendYields
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2021	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions		usd
	mssv	Derivative Instruments Additions DerivativeInstrumentsAdditions		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001760026

Files In Submission

Name	View Source	Status
0001213900-22-048156-index-headers.html	Edgar Link	pending
0001213900-22-048156-index.html	Edgar Link	pending
0001213900-22-048156.txt	Edgar Link	pending
0001213900-22-048156-xbrl.zip	Edgar Link	pending
f10q0622ex31-1_mesonumis.htm	Edgar Link	pending
f10q0622ex31-2_mesonumis.htm	Edgar Link	pending
f10q0622ex32-1_mesonumis.htm	Edgar Link	pending
f10q0622_mesonumis.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mssv-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
mssv-20220630_def.xml	Edgar Link	unprocessable
mssv-20220630_pre.xml	Edgar Link	unprocessable
mssv-20220630_lab.xml	Edgar Link	unprocessable
f10q0622_mesonumis_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mssv-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

2022 Q3 Form 10-Q Financial Statement

#000121390022048156 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG Regenerative Medical Technology Group Inc. Stock $rmtg

2022 Q3 Form 10-Q Financial Statement

#000121390022048156 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg